Core Viewpoint - The article emphasizes the commitment to advancing research in the field of biomedicine, particularly focusing on neurodegenerative diseases and the development of innovative chiral nanomedicines [1] Group 1: Research Focus - The company aims to address cutting-edge challenges in the biomedicine sector, specifically targeting neurodegenerative diseases through new principles, mechanisms, and targets for intervention [1] - There is a strong emphasis on achieving breakthroughs in core technologies related to drug development [1] Group 2: Collaboration and Application - The company is actively responding to the "dual high synergy" mechanism by engaging deeply with clinical doctors and the industry [1] - The goal is to transition more research outcomes from the laboratory to clinical applications, ultimately benefiting the public [1]